journal
MENU ▼
Read by QxMD icon Read
search

Clinical Breast Cancer

journal
https://www.readbyqxmd.com/read/29150351/combined-hormonal-contraceptive-use-and-risk-of-breast-cancer-in-a-population-of-women-with-a-family-history
#1
Giovanni Grandi, Angela Toss, Angelo Cagnacci, Luigi Marcheselli, Silvia Pavesi, Fabio Facchinetti, Stefano Cascinu, Laura Cortesi
BACKGROUND: We estimated the association between combined hormonal contraceptive (CHC) use and breast cancer (BC) incidence in a well-selected population of women at familial risk of BC at the Modena Family Cancer Clinic. MATERIALS AND METHODS: We performed a retrospective cohort study by reviewing the data from 2527 women (4.5% BRCA mutation carriers, 72.2% high risk, and 23.3% intermediate risk using the Modena criteria and the Tyrer-Cuzick model). RESULTS: We did not find any specific feature of breast cancer (infiltration, hormone receptor and HER2 status, onset before age 35 years, multiple diagnoses) in the CHC users (P > ...
November 14, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29153866/a-phase-i-trial-of-the-pi3k-inhibitor-buparlisib-combined-with-capecitabine-in-patients-with-metastatic-breast-cancer
#2
Autumn J McRee, Paul K Marcom, Dominic T Moore, William C Zamboni, Zachary A Kornblum, Zhiyuan Hu, Rachel Phipps, Carey K Anders, Katherine Reeder-Hayes, Lisa A Carey, Karen E Weck, Charles M Perou, E Claire Dees
BACKGROUND: Buparlisib is an oral pan-class I phosphotidyinositol-3-kinase (PI3K) inhibitor. The present phase I study evaluated the safety, pharmacokinetics, and efficacy of buparlisib with capecitabine in patients with metastatic breast cancer. PATIENTS AND METHODS: Patients received buparlisib once daily (range, 50 to 100 mg) for 3 weeks with capecitabine twice daily (range, 1000 to 1250 mg/m(2)) for 2 weeks with a 1-week break. Dose escalation used a traditional "3 + 3" design with standard definitions of dose-limiting toxicity (DLT) and maximum tolerated dose...
October 28, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29153775/weekly-paclitaxel-and-carboplatin-plus-bevacizumab-as-first-line-treatment-of-metastatic-triple-negative-breast-cancer-a%C3%A2-multicenter-phase-ii-trial-by-the-hellenic-oncology-research-group
#3
Emmanouil Saloustros, Michail Nikolaou, Konstantinos Kalbakis, Aris Polyzos, Charalampos Christofillakis, Nikolaos Kentepozidis, Nikolaos Pistamaltzian, Charalampos Kourousis, Lampros Vamvakas, Vasilios Georgoulias, Dimitris Mavroudis
BACKGROUND: Triple-negative breast cancer (TNBC) lacks a standard targeted therapeutic strategy and is treated with conventional cytotoxic agents. Because of the sensitivity of TNBC to platinum compounds and the synergistic effect of bevacizumab with paclitaxel we investigated the efficacy and toxicity of weekly paclitaxel and carboplatin in combination with bevacizumab as first-line treatment in metastatic TNBC. PATIENTS AND METHODS: This phase II study followed the Simon's 2-stage optimal design...
October 24, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29128193/vitamin-d-levels-vitamin-d-receptor-polymorphisms-and-inflammatory-cytokines-in-aromatase-inhibitor-induced-arthralgias-an-analysis-of-cctg-ma-27
#4
Polly Niravath, Bingshu Chen, Judy-Anne W Chapman, Sandeep K Agarwal, Robert L Welschhans, Tim Bongartz, Krishna R Kalari, Lois E Shepherd, John Bartlett, Kathleen Pritchard, Karen Gelmon, Susan G Hilsenbeck, Mothaffar F Rimawi, C Kent Osborne, Paul E Goss, James N Ingle
BACKGROUND: Approximately half of women taking aromatase inhibitor (AI) therapy develop AI-induced arthralgia (AIA), and many might discontinue AI therapy because of the pain. Using plasma samples from the MA.27 study, we assessed several factors potentially associated with AIA. PATIENTS AND METHODS: MA.27 is a phase III adjuvant trial comparing 2 AIs, exemestane versus anastrozole. Within an 893-participant nested case-control AIA genome-wide association study, we nested a 72 AIA case-144 control assessment of vitamin D plasma concentrations, corrected for seasonal and geographic variation...
October 16, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29100726/expanding-implementation-of-acosog-z0011-in-surgeon-practice
#5
Anna Weiss, Elizabeth A Mittendorf, Sarah M DeSnyder, Rosa F Hwang, Vivian Bea, Isabelle Bedrosian, Karen Hoffman, Beatriz Adrade, Aysegul A Sahin, Henry M Kuerer, Kelly K Hunt, Abigail S Caudle
BACKGROUND: After publication of American College of Surgeons Oncology Group (ACOSOG) Z0011, surgeons at our institution limited axillary surgery to sentinel lymph node dissection (SLND) in 76% of patients meeting trial eligibility criteria. Our study objective was to assess incorporation of the trial data into practice 5 years later. PATIENTS AND METHODS: Patients with clinical T1-2, N0 invasive breast cancer undergoing breast conserving surgery were included. Comparisons were made between patients who underwent axillary lymph node dissection (ALND) and those that had no further surgery...
October 13, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29129549/application-of-acosog-z1071-effect-of-results-on-patient-care-and-surgical-decision-making
#6
Jacquelyn A V Palmer, Teresa Flippo-Morton, Kendall K Walsh, Lejla Hadzikadic Gusic, Terry Sarantou, Myra M Robinson, Richard L White
BACKGROUND: The ACOSOG (American College of Surgeons Oncology Group) Z1071 assessed the feasibility of performing sentinel lymph node biopsy (SLNB) in node-positive patients who completed neoadjuvant chemotherapy (NACT). Historically, adoption of clinical research into practice takes years. The goal of this study was to determine the effect of Z1071 on our practice. MATERIALS AND METHODS: This is a retrospective review of Z1071's influence on a single institution's practice...
October 12, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29153774/palbociclib-induced-thrombotic-microangiopathy-in-metastatic-breast-cancer-patient-surviving-for-18-years-case-report-and-review-of-the-literature
#7
Hanan Raiss, Julien Péron, Sophie Tartas, Véronique Trillet-Lenoir, Gilles Freyer, Hassan Errihani
No abstract text is available yet for this article.
October 7, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29102711/pleomorphic-lobular-carcinoma-in-situ-diagnosed-by-breast-core-biopsy-clinicopathologic-features-and-correlation-with-subsequent-excision
#8
Tianhua Guo, Yihong Wang, Nella Shapiro, Susan Fineberg
INTRODUCTION: Pleomorphic lobular carcinoma in situ (PLCIS) is a variant of LCIS with high-grade morphologic features. The number of case series studying PLCIS is limited, and clinical management of patients with PLCIS is controversial. We report a breast core biopsy (BCBx) series of PLCIS. MATERIALS AND METHODS: We reviewed 37 cases of PLCIS with or without microinvasion diagnosed by BCBx. PLCIS was defined as dyscohesive cells showing acinar expansion and loss of immunohistochemical membranous expression of e-cadherin or beta-catenin with nuclear pleomorphism with at least 2- to 3-fold variation in nuclear size, membrane irregularities, and variably prominent nucleoli...
October 7, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29100727/operative-and-therapeutic-advancements-in-breast-cancer-metastases-to-the-brain
#9
REVIEW
Rahul Jandial, Reid Hoshide, J Dawn Waters, George Somlo
Patients with breast cancer are surviving longer as the state of the art for care advances. Because patients are surviving longer with primary breast cancer, the incidence of secondary metastatic disease has risen. Metastatic breast cancer to the brain was once thought to be universally fatal. While it is still quite lethal, its treatment after diagnosis is increasingly safe and effective. Critical progress has been made in understanding the interaction between breast metastases and the neural niche, neuroimaging of functional anatomy, minimally invasive image-guided brain surgery, characterizing subtypes of breast cancer based on molecular and genetic profiles, and individualized pharmaceuticals and immunotherapies...
October 7, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29089281/influence-of-biologic-subtype-of-inflammatory-breast-cancer-on-response-to-neoadjuvant-therapy-and-cancer-outcomes
#10
Tina J Hieken, Brittany L Murphy, Judy C Boughey, Amy C Degnim, Katrina N Glazebrook, Tanya L Hoskin
BACKGROUND: Few data exist on the influence of tumor biologic subtype on treatment response and outcomes for inflammatory breast cancer (IBC). We examined a contemporary cohort of IBC patients treated with current targeted systemic therapies, selected on the basis of tumor biologic subtype, to evaluate pathologic treatment response and cancer outcomes across biologic subtypes. PATIENTS AND METHODS: We studied 57 clinical stage T4dM0 IBC patients operated on at our institution from October 2008 to July 2015...
October 7, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29138067/the-prognostic-effect-of-changes-in-tumor-stage%C3%A2-and-nodal-status-after-neoadjuvant-chemotherapy-in-each-primary-breast-cancer%C3%A2-subtype
#11
Naoki Hayashi, Yuko Takahashi, Naoko Matsuda, Hiroko Tsunoda, Atsushi Yoshida, Koyu Suzuki, Seigo Nakamura, Hideko Yamauchi
BACKGROUND: Although the prognostic value of pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) depends on the intrinsic subtype of breast cancer, it is not clear whether chemosensitivity itself, shown by a decreasing tumor burden after NAC, contributes to improved prognosis in primary breast cancer patients, especially in patients with non-pCR. The aim of this study was to assess the prognostic effect of changes in tumor stage or nodal status after NAC in each primary breast cancer subtype...
October 3, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29066138/evidence-on-synthesized-two-dimensional-mammography-versus-digital-mammography-when-using-tomosynthesis-three-dimensional-mammography-for-population-breast-cancer-screening
#12
REVIEW
Nehmat Houssami
One limitation of using digital breast tomosynthesis (3-dimensional [3D] mammography) technology with conventional (2-dimensional [2D]) mammography for breast cancer (BC) screening is the increased radiation dose from dual acquisitions. To resolve this problem, synthesized 2D (s2D) reconstruction images similar to 2D mammography were developed using tomosynthesis acquisitions. The present review summarizes the evidence for s2D versus digital mammography (2D) when using tomosynthesis (3D) for BC screening to address whether using s2D instead of 2D (alongside 3D) will yield similar detection measures...
September 28, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29050918/assessing-the-effect-of-lifetime-contralateral-breast-cancer-risk-on-the-selection-of-contralateral-prophylactic-mastectomy-for-unilateral-breast-cancer
#13
John V Hegde, Xiaoyan Wang, Deanna J Attai, Maggie L DiNome, Amy Kusske, Anne C Hoyt, Sara A Hurvitz, Joanne B Weidhaas, Michael L Steinberg, Susan A McCloskey
INTRODUCTION: Contralateral prophylactic mastectomy (CPM) rates are rising, with fear implicated as a contributing factor. This study used a contralateral breast cancer (CBC) risk stratification tool to assess whether the selection of CPM is reflective of future CBC risk. PATIENTS AND METHODS: This retrospective study evaluated 404 women with unilateral breast cancer treated with breast conservation, unilateral mastectomy, or bilateral mastectomy within a single multidisciplinary clinic...
September 27, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29079443/radiofrequency-ablation-of-breast-cancer-a-retrospective-study
#14
Toshikazu Ito, Shoji Oura, Shinji Nagamine, Masato Takahashi, Naohito Yamamoto, Noboru Yamamichi, Mitsuharu Earashi, Hiroyoshi Doihara, Shigeru Imoto, Shoshu Mitsuyama, Kohei Akazawa
PURPOSE: To validate the safety and efficacy of percutaneous radiofrequency ablation (RFA) of breast carcinomas. METHODS: This retrospective study was conducted by the Breast Cancer Society for Minimally Invasive Therapy following approval from institutional review boards, and with the written informed consent of patients. A total of 386 patients with breast cancer treated with RFA at 10 institutions between July 2003 and June 2009 were identified and included in the analysis...
September 25, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29054689/breast-cancer-survivorship-care-variations-between-adjuvant-chemotherapy-regimens
#15
Alexis D Leal, Holly Van Houten, Lindsey Sangaralingham, Rachel A Freedman, Ahmedin Jemal, Heather B Neuman, Tufia C Haddad, Robert W Mutter, Theresa H M Keegan, Sarah S Mougalian, Charles L Loprinzi, Cary P Gross, Nilay Shah, Kathryn J Ruddy
BACKGROUND: Treatment-related toxicity can vary substantially between chemotherapy regimens. In this study we evaluated the frequency of outpatient office visits among a cohort of early stage breast cancer survivors after completion of 4 different adjuvant chemotherapy regimens to better understand how differences in toxicities between regimens might affect health care use. MATERIALS AND METHODS: We analyzed administrative claims data from a US commercial insurance database (OptumLabs) to identify women who received adjuvant doxorubicin/cyclophosphamide (AC), AC followed or preceded by docetaxel or paclitaxel (AC-T), AC concurrent with docetaxel or paclitaxel (TAC), or docetaxel/cyclophosphamide (TC) between 2008 and 2014...
September 22, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29097108/everolimus-plus-letrozole-for-treatment-of-patients-with-hr-her2-advanced-breast-cancer-progressing-on-endocrine-therapy-an-open-label-phase-ii-trial
#16
Tamar Safra, Bella Kaufman, Luna Kadouri, Noa Efrat Ben-Baruch, Larisa Ryvo, Bella Nisenbaum, Ella Evron, Rinat Yerushalmi
PURPOSE: In the Breast cancer trials of OraL EveROlimus-2 (BOLERO-2) trial, everolimus plus exemestane improved progression-free survival (PFS) in patients with hormone receptor-positive (HR(+)), human epidermal growth factor receptor 2-negative (HER2(-)) advanced breast cancer (ABC) recurring or progressing on/after prior endocrine therapy (ET), suggesting that dual blockade using targeted therapy and ET was an effective treatment option. Here, we investigated the clinical benefit of combining everolimus with different endocrine partner, letrozole, in a similar patient population...
September 19, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29066139/role-of-bi-rads-ultrasound-subcategories-4a-to-4c-in-predicting-breast-cancer
#17
Miguel Angelo Spinelli Varella, Jackson Teixeira da Cruz, Andrea Rauber, Ivana Santos Varella, James Freitas Fleck, Luis Fernando Moreira
BACKGROUND: The Breast Imaging Reporting and Data System (BI-RADS) ultrasound (US) categorization revised in 2013 by the American College of Radiology resulted in unquestionable standardization of reports and confirmed category 3 and 5 as benign and malignant lesions, respectively. In contrast, suspected images (category 4) have subcategorization criteria, although theses have been detailed difficult to apply. The aim of the present study was to determine the role of the US 4A to 4C BI-RADS subcategories in predicting malignancy...
September 19, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29042129/epigenetic-pathways-offer-targets-for-ovarian-cancer-treatment
#18
Melina-Theoni Gyparaki, Athanasios G Papavassiliou
No abstract text is available yet for this article.
September 19, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29033240/single-nucleotide-polymorphisms-in-the-acylphosphatase-2-gene-and-the-snp-snp-interactions-on-the-risk-of-breast-cancer-in-chinese-han-women
#19
Junben Wu, Shujing Wang, Fanglan Liu, Shuluan Li
INTRODUCTION: The purpose of this study was to investigate the impact of single nucleotide polymorphisms (SNPs) in the acylphosphatase 2 gene and the SNP-SNP interactions on breast cancer (BC) risk in Chinese Han women. PATIENTS AND METHODS: A logistic regression model was used to examine the association between SNPs and BC risk. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated. Generalized multifactor dimensionality reduction was employed to analyze the SNP-SNP interaction...
September 19, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29033239/socioeconomic-factors-health-behavior-and-late-stage-diagnosis-of-breast-cancer-considering-the-impact-of-delay-in-diagnosis
#20
Mostafa Dianatinasab, Mohammad Mohammadianpanah, Nima Daneshi, Mohammad Zare-Bandamiri, Abbas Rezaeianzadeh, Mohammad Fararouei
BACKGROUND: Stage of cancer at diagnosis is one of the most important factors in patient prognosis. By controlling for diagnostic delay, this study aimed to identify factors associated with late-stage breast cancer (BC). PATIENTS AND METHODS: From November 2014 to January 2017, required information on 497 patients who were newly diagnosed with BC was obtained from patients' medical records. Logistic regression was used to measure the association between cancer stage and study variables...
September 19, 2017: Clinical Breast Cancer
journal
journal
34827
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"